Spotlight on Amivantamab (JNJ-61186372) for EGFR Exon 20 Insertions Positive Non-Small Cell Lung Cancer

Spotlight on Amivantamab (JNJ-61186372) for EGFR Exon 20 Insertions Positive Non-Small Cell Lung Cancer

Danielle Brazel,1 Misako Nagasaka1– 3 1Department of Medicine, University of California Irvine School of Medicine, Orange, CA, USA; 2Chao Family Comprehensive Cancer Center, Orange, CA, USA; 3St. Marianna University School of Medicine, Kawasaki, JapanCorrespondence: Misako NagasakaDepartment of Medi...

Full description

Bibliographic Details
Main Authors: Brazel D, Nagasaka M
Format: Article
Language:English
Published: Dove Medical Press 2021-12-01
Series:Lung Cancer: Targets and Therapy
Subjects:
amivantamab
epidermal growth factor receptor
mesenchymal-epithelial transition factor
met
non-small cell lung cancer
tyrosine kinase inhibitors
Online Access:https://www.dovepress.com/spotlight-on-amivantamab-jnj-61186372-for-egfr-exon-20-insertions-posi-peer-reviewed-fulltext-article-LCTT

Internet

https://www.dovepress.com/spotlight-on-amivantamab-jnj-61186372-for-egfr-exon-20-insertions-posi-peer-reviewed-fulltext-article-LCTT

Similar Items